D. Boral Capital Reaffirms “Buy” Rating for VolitionRx (NYSE:VNRX)

VolitionRx (NYSE:VNRX)‘s stock had its “buy” rating restated by investment analysts at D. Boral Capital in a report released on Thursday,Benzinga reports. They presently have a $5.00 price target on the stock.

A number of other equities analysts have also recently issued reports on the stock. Benchmark restated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. StockNews.com started coverage on shares of VolitionRx in a research report on Thursday. They set a “sell” rating for the company.

VolitionRx Trading Up 1.0 %

Shares of VNRX opened at $0.55 on Thursday. The stock has a market cap of $50.97 million, a P/E ratio of -1.53 and a beta of 1.09. The company has a 50-day moving average of $0.60 and a two-hundred day moving average of $0.64. VolitionRx has a 12-month low of $0.43 and a 12-month high of $1.02.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Lagoda Investment Management L.P. lifted its position in shares of VolitionRx by 24.3% during the fourth quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after purchasing an additional 1,481,000 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after purchasing an additional 95,900 shares in the last quarter. Northern Trust Corp lifted its position in shares of VolitionRx by 32.0% during the fourth quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after purchasing an additional 28,579 shares in the last quarter. Millennium Management LLC acquired a new position in shares of VolitionRx during the fourth quarter worth $36,000. Finally, Two Sigma Securities LLC acquired a new position in shares of VolitionRx during the fourth quarter worth $29,000. 8.09% of the stock is owned by institutional investors and hedge funds.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.